Cumulative incidence of MR^4.5by BCR-ABL levels at 3 months in evaluable patients. Panels show MR^4.5 achieved in the nilotinib 300 mg twice-daily (A), nilotinib 400 mg twice-daily (B), and imatinib once-daily (C) arms. Patients with atypical transcripts at baseline or unevaluable or missing PCR assessments at 3 months, or who achieved MR^4.5 by 3 months, were excluded.